Collateral for a security interest recorded Aug 25, 2022 (Midcap Financial Trust).
Lapsed May 27, 2026 on the fee record · Medium confidence
20-year base term ends Jan 22, 2030
Why Medium: A parent in the chain could not be resolved.
Third maintenance fee unpaid; grace period ended.
Held by Rigel Pharmaceuticals, Inc.
Filed Sep 10, 2013 as application 14/023,158 · Granted May 27, 2014
Base term, 20 years from filing
Today
Lapsed May 27, 2026
2010
2030
Clock starts
Jan 22, 2010
Jan 22, 2010
No longer in force
May 27, 2026
May 27, 2026
Granted
May 27, 2014
May 27, 2014
Term would have run to
Jan 22, 2030
Jan 22, 2030
base term
after the term ends
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
13
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
Its term would have run to Jan 22, 2030: its 20-year base term, with no adjustment for prosecution delay. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 22, 2010, when application 12/692,493, the earliest non-provisional in its chain, was filed (this one was filed Sep 10, 2013); a parent in its chain could not be resolved (the next row) | Jan 22, 2030 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | lapsed May 27, 2026 | High confidence |
| Computed term end | The steps above, in order | May 27, 2026 | Medium confidence |
This family
| US 8,324,200 | In force Jun 2030 | Jun 2030 |
| US 8,563,716 | Lapsed on the fee record Oct 2025 | Oct 2025 |
| US 8,507,675 | Lapsed on the fee record Aug 2025 | Aug 2025 |
| US 8,530,656 | Lapsed on the fee record Sep 2025 | Sep 2025 |
| US 8,524,901 | Lapsed on the fee record Sep 2025 | Sep 2025 |
| US 8,563,569 | Lapsed on the fee record Oct 2025 | Oct 2025 |
| US 9,084,795 | In force Jan 2030 | Jan 2030 |
| US 8,735,400 | this patent May 2026 | May 2026 |
8 of 13 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 19, 2013 Reel 31823, frame 890 | Li, Hui; Chen, Yan; Taylor, Vanessa; Singh, Rajinder | Rigel Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Aug 25, 2022 Reel 61327, frame 712 | Rigel Pharmaceuticals, Inc. | Midcap Financial Trust | Security Interest |
| May 8, 2026 Reel 75576, frame 880 | Rigel Pharmaceuticals, Inc. | Midcap Funding IV Trust | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Citations
13
later US patents cite this one
That is above the median of utility patents granted in 2014 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.